Biosynex SA Reports Revenue Growth and Restructures for Future Stability

Biosynex SA ( (FR:ALBIO) ) has shared an update.

Biosynex SA reported a 9% increase in revenue for 2024, reaching €101.4 million, driven by export sales and the Pharmacy Division’s resilience. The company is undergoing restructuring efforts, including renegotiating bank debt, closing unprofitable sites, and reducing staff, aiming to enhance operational profitability and align expenses with activity levels. These efforts are expected to save over €7 million annually from 2025, positioning Biosynex for improved financial stability and market competitiveness.

More about Biosynex SA

Biosynex SA operates in the healthcare industry, focusing on pharmacy and diagnostic products. The company is expanding internationally and has a strong presence in both Europe and the USA, with a significant emphasis on export growth.

YTD Price Performance: 55.52%

Average Trading Volume: 384

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €22.71M

See more data about ALBIO stock on TipRanks’ Stock Analysis page.